Skip to main content
. Author manuscript; available in PMC: 2024 Apr 25.
Published in final edited form as: JACC Heart Fail. 2023 Feb;11(2):211–223. doi: 10.1016/j.jchf.2022.11.007

Figure 2. Background Medical Therapy in the VICTORIA Trial and GWTG-HF Registry.

Figure 2.

Shows the medications by VICTORIA eligible patients, FDA label patients, hospitalized HF with EF <45% population, and VICTORIA randomized trial population. Percentages represent proportion of patients prescribed these medications at discharge among all groups except VICTORA trial population where the percentages represent the proportion of patients who were on these medications at baseline.